李家平(中山大學附屬第一醫院腫瘤介入科主任)

李家平(中山大學附屬第一醫院腫瘤介入科主任)

本詞條是多義詞,共2個義項
更多義項 ▼ 收起列表 ▲

李家平,男,江蘇揚州人,中山大學醫學博士,美國南加州大學博士後,現任中山大學附屬第一醫院腫瘤介入科主任、教授、主任醫師、博士生導師,優秀青年人才培養對象,首屆羊城好醫生,2015年獲國際腫瘤冷凍學會傑出成就獎,2017年被授予“國之名醫”優秀示範稱號,長期從事腫瘤與血管疾患的微創介入與靶向治療。2013年任第3屆亞太腫瘤介入學大會執行主席,2014、2015年任肝癌微創與綜合治療廣州國際高峰論壇執行主席。

基本介紹

  • 中文名:李家平
  • 國籍:中國
  • 民族:漢
  • 出生地江蘇揚州
  • 出生日期:1969年9月10日
  • 職業:醫生、教授
  • 畢業院校:中山大學
個人信息,教育與學術經歷,社會兼職,主要研究領域,代表性論著,

個人信息

李家平
擅長於腫瘤與血管疾患的診斷與介入治療,特別是對原發性肝癌轉移性肝癌肺癌膽管癌胰腺癌膀胱癌盆腔腫瘤、兒童腹部惡性實體瘤血管瘤血管畸形的診斷與介入治療(包括局部腫瘤的化療栓塞、射頻氬氦刀冷凍、微波消融、粒子與支架植入、藥盒埋置、全身規範化療和分子靶向治療),同時在肝硬化門脈高壓症TIPSS治療、頸動脈體瘤、血管閉塞性疾病、主動脈瘤及夾層腔內治療等方面也積累著豐富的診療經驗。現重點研究腫瘤的微創介入與靶向治療,以及肝硬化門脈高壓症的經頸靜脈肝內門體靜脈分流術。

教育與學術經歷

2004年6月獲中山大學臨床博士學位。2004年在韓國Asan醫療中心接受微創介入學臨床技能訓練,2008年6月-2009年9月在美國南加州大學Hoffman醫學研究中心從事博士後研究工作,在國內較早進行“MAT基因的肝癌相關性研究”。主持國家自然科學基金研究面上項目3項,參與2項;主持包括教育部留學回國人員啟動基金項目在內的省部級科研項目15項,中山大學重大醫學臨床5010科研項目1項。主編人衛版專著《肝癌微創介入治療學》,參編9部。在核心醫學雜誌上發表論文130餘篇,SCI收錄論著近40餘篇,The Oncologist, Oncotarget, Cardiovasc Intervent Radiology,Journal of Vascular & Interventional Radiology,Target Oncology, Tumor Biology, PLoS One, Oncotarget, BMC Cancer,American J Pathology, J Urology,Neurosurgery 等國際SCI期刊上發表論著。多次應邀在國內外標誌性腫瘤與介入醫學會議上發言(CSCOASCO、RSNA、SIR、ESMO),並建立了廣泛的國際合作研究關係。

社會兼職

現任中國醫師協會介入醫師分會全國青委會主任委員、腫瘤介入專業委員會副主任委員、中華醫學會放射學分會介入專家委員會委員、國際肝膽胰學會介入學分會副主任委員、中國抗癌協會腫瘤微創治療專業委員會青委會副主任委員、肝癌專業委員會副主任委員、影像引導下腫瘤消融專業委員會副主任委員、血管治療分會副主任委員、國際冷凍治療學會常務理事、亞洲冷凍治療學會副主席、中國抗癌協會粒子專業委員會青委會主任委員、廣州抗癌協會腫瘤微創治療專業委員會副主任委員、歐洲放射學會委員、廣東省肝臟病學會肝癌治療MDT專業委員會副主任委員、廣東省醫學影像中心管理專業委員會常委,腫瘤康復與姑息治療專業委員會常委,廣東省中西醫結合全身介入專業委員會常委,廣東省醫學會介入分會委員、醫師協會常委,教育部留學歸國人員基金評審專家,教育部博士後基金評審專家,國家自然科學基金評審專家。包括European Radiology,PLoS One, BMC Cancer, CardiovascIntervent Radiology,Journal of Vascular & Interventional Radiology, Neurosurgery, JUrology, J Vasc Surg等多家國際專業雜誌的評閱人和撰稿人。

主要研究領域

1. 肝癌血管生成中的調控機制及分子影像學監測
2. 腫瘤冷凍消融與免疫調節的臨床與基礎研究
3. 肝癌的基因治療與分子影像(基因成像、細胞成像)
4. 肝硬化門脈高壓症的經頸靜脈肝內門體靜脈分流術的基礎與臨床
5. 基於現代影像融合技術的腫瘤微創精準治療

代表性論著

1. Zhang Y, Huang G, Wang Y, Liang L, Peng B, Fan W, Yang J, Huang Y, Yao W, Li J*(李家平)(通訊作者).Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.Oncologist. 2016 Aug 2. pii: theoncologist.2016-0094. [Epub ahead of print].
2. Wang Y, Cui W, Fan W, Zhang Y, Yao W, Huang K, Li J*(李家平)(通訊作者).Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma.Oncotarget. 2016 Jun 17. doi: 10.18632/oncotarget.10116. [Epub ahead of print].
3. Fan W, Niu L, Wang Y, Zhang Y, Yao X, Tan G, Yang J, Li J*(李家平)(通訊作者).Percutaneous computed tomography-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy.Oncotarget. 2016 May 19. doi: 10.18632/oncotarget.9476. [Epub ahead of print]
4. Wen-Zhe Fan, Li-Zhi Niu, Yu Wang, Xue-Hua Yao, Ying-Qiang Zhang, Guo-Sheng, Tan, Jian-Yong Yang, Jia-Ping Li*(李家平)(通訊作者). Alleviating pain effect of percutaneous CT-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: initial experience of 39 patients. Journal of Vascular and Interventional Radiology.2016 Sep 8. pii: S1051-0443(16)30336-0. doi: 10.1016/j.jvir.2016.06.034. [Epub ahead of print].
5. Yu Wang*, Wei Cui*(共同第一作者), Wenzhe Fan, Yingqiang Zhang, Wang Yao, Kunbo Huang, Jiaping Li*(李家平)(通訊作者). Percutaneous Intraductal Radiofrequency Ablation in the Management of Unresectable Bismuth Types III and IV Hilar Cholangiocarcinoma. Oncotarget.2016 Jun 17. doi: 10.18632/oncotarget.10116. [Epub ahead of print].
6. Yu Wang*, Wei Cui*(共同第一作者), Jia Wen, Wenzhe Fan, Yingqiang Zhang, Wang Yao, Kunbo Huang, Jiaping Li*(李家平)(通訊作者). Raltitrexed Based Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Single-center Randomized Controlled Study. 2016 Chemotherapy (accepted).
7. Yingqiang Zhang, Wenzhe Fan, Yu Wang, Ligong Lu, Sirui Fu, Jianyong Yang, Yonghui Huang, Wang Yao, Jiaping Li*(李家平)(通訊作者). Sorafenib with or without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis. Oncologist. 2015 Dec; 20(12):1417-24.
8. Yingqiang Zhang, Wenzhe Fan, Kangshun Zhu, Ligong Lu, Sirui Fu, Jinhua Huang, Yu Wang, Jianyong Yang, Yonghui Huang, Wang Yao, Jiaping Li*(李家平)(通訊作者). Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. Oncotarget. 2015 Sep 15;6(27):24550-9.
9. Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J(李家平)(通訊作者).Neutrophil-to- Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization. PLoS One. 2015 Mar 5; 10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.
10. Jiaping Li(李家平)(通訊作者), Fujun Zhang, Jianyong Yang, Yingqiang Zhang, Yu Wang, Wenzhe Fan, Yonghui Huang, Wei Wang, Henry Ran, Shi Ke. Combination of individualized local control and target-specific agent to improve unrespectable liver cancer managements: a matched case-control study. Targeted Oncology. 2015 Jun; 10(2):287-95.
11. Yi Jin, Jianning Chen, Zhiying Feng, Zhigang Zhang, Yu Wang, Wenzhe Fan, Jiaping Li(李家平)(通訊作者). OPN and αvβ3 Expression are Predictors of Disease Severity and Worse Prognosis in Hepatocellular Carcinoma. PLOS One. 2014, 3; 9(2):e87930. PMID:24498405
12. Jin Y,Chen J,Feng Z,Fan W, Wang Y, Li J(李家平)(通訊作者), Tong D. The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma. Tumour biology, 2014 Oct;35(10):9905-10.
13. Fu SR, Zhang YQ, Li Y, Hu BS, He X, Huang JW, Zhan MX, Lu LG, Li JP(李家平)(通訊作者). Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.Asian Pac J Cancer Prev. 2014; 15(7):3151-6.
14. Jin Y, Tong D, Shen J, Yang J, Li J.(李家平)(通訊作者)Establishment of implantationtumormodelsofhepatocellularcarcinoma in Wistarrats. Tumour Biol. 2014 Sep; 35(9):9079-83.
15. Qi Zhou, Yafeng Wang, Baogang Peng, Lijian Liang, Jiaping Li(李家平)(通訊作者).The Roles of Notch1 Expression in the Migration of Intrahepatic Cholangiocarcinoma. BMC Cancer.2013, 13:244.
16. Gao ZH, Yin JQ, Liu DW, Meng QF, Li JP(李家平)(通訊作者).Preoperative easily misdiagnosed telangiectatic osteosarcoma: clinical-radiologic-pathologic correlations. Cancer Imaging. 2013, 11; 13(4):520-6.
17. Junxing Chen, Zhijun Yao, Shaopeng Qiu, Lingwu Chen, Yu Wang,Jianyong Yang, Jiaping Li(李家平)(通訊作者). Comparingintra-arterial chemotherapy combined with intravesical chemotherapy versusintravesical chemotherapy alone: a randomised prospective pilot study for T1G3bladder transitional cell carcinoma after bladder-preserving surgery. Cardiovasc Intervent Radiol. 2013, 36(6)1521-1526.
18. Yi Jin, Da-yue Tong, Jian-ning Chen, Zhi-ying Feng, Jian-yong Yang ,Chun-kui Shao, Jia-ping Li(李家平)(通訊作者). Overexpressionof osteopontin αvβ3 and Pim-1 associated with prognostically importantclinicopatholo.PLOS One. 2012, 7(10), e48575.
19. Wang Yu, Lian Fan, Li Jiaping(李家平), et al. Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats. Journal of Translational Medicine. 2012, 10(1): 133.
20. Chen JX, Deng N, Chen X, Chen LW, Qiu SP, Li XF, Li JP(李家平)(通訊作者).A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev. 2012; 13(5):2229-34.
21. Wu J, Zhou Q, Wang Y, Zhou X, Li J(李家平)(通訊作者). MNT inhibits the migration of human hepatocellular carcinoma SMMC7721 cells. Biochem Biophys Res Commun. 2012 Feb 3; 418(1):93-7.
22. Qi Zhou, Yafeng Wang, Xiangbing Zhou, Baogang Peng, Jianyong Yang, Lijian Liang1, Jiaping Li(李家平)(通訊作者). Prognostic Analysis for Treatment Modalities in Hepatocellular Carcinomas with Portal Vein Tumor Thrombi. Asian Pacific J Cancer Prev, 2012, 12, 2847-2850.
23. Li J(李家平),Ramani K, Sun Z, Zee C, Grant EG, Yang H, Xia M, Oh P, Ko K, Mato JM, Lu SC. Forced Expression of Methionine Adenosyltransferase 1A(MAT1A)in Human Hepatoma Cells Suppresses in vivo Tumorigenicity in Mice.American Journal of Pathology, 2010, 176(5):2456-2466.
24. Jia-Ping Li(李家平),Jian-Ping Chu, Pilsoo Oh, Zhi Li, Wei Chen, Yong-Hui Huang, Jian-Yong Yang. Characterizing the clinicopathologic findings of transarterial chemoembolization in wilms’ tumor. J Urology, 2010, 183(3):1138-1144.
25. Jiaping Li(李家平), Shenming Wang, Chishing Zee, Jianyong Yang, Zhuang Wenquan, Wei Chen, Xiaoxi Li,Weiming Lv, Yonghui Huang, Songqi Li. Preoperative Angiography and Transarterial Embolizationin The Management of Carotid Body tumor-A Single Centre 10 Years Experience. Neurosurgery, 2010, 67(4): 941-948.
26. Yi Jin, Jia-Ping Li(李家平)(並列第一作者), Dan He, Lu-Ying Tang, Chi-shing Zee, Shao-Zhong Guo, Jing Zhou, Jian-Ning Chen, Chun-Kui Shao. Clinical Significance of Human Telomerase RNA Gene (hTERC)Amplification in Cervical Squamous Cell Lesions Detected byFluorescence in Situ Hybridization.Asian Pacific J Cancer Prev,2012, 12, 1167-1171
27. J. Li(李家平), W.Fan, J. Yang, Y. Wang, W. Chen, Y. Zhang. Experimental study on the transcriptional targeting gene therapy of double suicide gene driven by hTERT promotor in hepatoma carcinoma. Journal of Vascular and Interventional Radiology.2012, 23(3) Suppl, S51-52.
28. J. Li(李家平),W.Fan, J.Yang,Y.Wang,W. Chen, X.Xie, M. Lu.Transcatheter arterial chemoembolization (TACE) combined percutaneous thermal ablation in large hepatocellular carcinoma: clinical observation of the efficacy and predictors of prognostic factors. Journal of Vascular and Interventional Radiology.2012, 23(3) Suppl , S19-S20.
29. Li JP(李家平), Chu JP, Yang JY, Chen W, Wang Y, Huang YH. Transcatheter selectively arterial chemoembolization in treatment of unresectable hepatoblastoma in infants and children. Cardiovasc Intervent Radiology, 2008, 31(6):1117-1123.
30. Yang H, Ko K, Xia M, Li TW, Oh P,Li J(李家平),Lu SC. Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice. Hepatology, 2010, 51(4):1291-1301.
31. Zhou F, Zee CS, Gong H, Shiroishi M, Li J(李家平).Differential changes in deep and cortical gray matters of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. J Comput Assist Tomogr, 2010, 34(3):431-436.
32. Lian F, Wang Y, Chen W, Li J(李家平), Zhan Z, Ye Y, Zhu Y, Huang J, Xu H, Yang X, Liang L, Yang J.Uterine Artery Embolization Combined with Local Methotrexate and Systemic Methotrexate for Treatment of Cesarean Scar Pregnancy with Different Ultrasonographic Pattern. Cardiovasc Intervent Radiol . 2012 Apr;35(2):286-91.
33. Jian-Ping Chu, Wei Chen, Jia-Ping Li(李家平), Zhuang WQ, Huang YH, Huang ZM, Yang JY. Clinicopathologic features and results of transcatheter arterial chemoembolization for osteosarcoma. Cardiovasc Inter Rad, 2007, 30:201-206.
34. Peng Bao-Gang, He Qiang,Li Jia-Ping(李家平),Zhou Fan. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. American journal of surgery, 2009, 198(3):313-318.
35. Yang H, Ramani K, Li TW, Oh P, Li J (李家平), Lu SC. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology, 2009, 49(6):1982-1991.
36. Yang H, Ko KS, Xia M, Li T, Oh P,Li J(李家平), Lu SC. Induction of Maf Proteins by Toxic Bile Acid Inhibits Expression of GSH Synthetic Enzymes and Contributes to Cholestatic Liver Injury in Mice" has been received by our editorial office. Hepatology, 2009, 49(6):1982-1991.
37. Xu HX, Liu L, Lu MD, Li HP, Liu GJ,Li JP(李家平). Three-dimensional power Doppler imaging in depicting vascularity in hepatocellular carcinoma.J Ultrasound Med, 2003, 22(11):1147-1154.
38. Wang S, Chang G, Li X, Hu Z, Li S, Yang J,Chen W, Li J(李家平).Endovascular treatment of arch and proximal thoracic aortic lesions. J Vasc Surg, 2008, 48(1): 64-68.
39. J. Li(李家平), W.Fan, J. Yang, Y. Wang, W. Chen, Y. Zhang. Experimental study on the transcriptional targeting gene therapy of double suicide gene driven by hTERT promotor in hepatoma carcinoma. Journal of Vascular and Interventional Radiology.2012, 23(3) Suppl, S51-52.
40. J. Li(李家平),W.Fan, J.Yang,Y.Wang,W. Chen, X.Xie, M. Lu.Transcatheter arterial chemoembolization (TACE) combined percutaneous thermal ablation in large hepatocellular carcinoma: clinical observation of the efficacy and predictors of prognostic factors. Journal of Vascular and Interventional Radiology.2012, 23(3) Suppl , S19-S20.
41. 範文哲, 張應強, 王於,姚學華,楊建勇, 李家平(通訊作者)經肝動脈化療栓塞糖尿病的危險因素肝細胞癌誘發肝源性分析,中華醫學雜誌,2014,94(33)
42. 張應強, 楊建勇, 王於,黃勇慧,範文哲, 李家平.TACE聯合索拉非尼治療大肝癌的療效與安全性分析,中華醫學雜誌, 93(13),987-991,2013
43. 陳俊星, 堯智軍, 丘少鵬, 陳凌武, 楊建勇, 李家平.T1G3膀胱癌保留膀胱術後動脈導管化療聯合膀胱灌注化療的療效分析.中華泌尿外科雜誌, 2012,32(2):99-103.
44. 範文哲, 楊建勇,陳偉,黃勇慧,王於,張應強,李家平(通訊作者).人端粒酶啟動子調控雙自殺基因治療肝癌的實驗研究.中華醫學雜誌.2011,91(43): 3080-3085.
45. 金亦,邵春奎,唐錄英,楊建勇,黃勇慧,李家平(通訊作者).肝細胞癌中Survivin與NF-κB蛋白的表達及其臨床意義.中華醫學雜誌.2011,91(36): 2542-2545.
46. 範文哲, 楊建勇,呂明德,謝曉燕,殷曉煜,黃勇慧,匡明,李鶴平,徐輝雄,李家平(通訊作者).TACE聯合經皮熱消融治療大肝癌的療效及預後分析. 中華醫學雜誌.2011, 91(31): 2190-2194.
47. 連帆, 王於, 範文哲, 楊岫巖, 許韓師, 陳偉, 楊建勇, 李家平(通訊作者). 經肝動脈同種異體脂肪幹細胞移植治療小鼠自身免疫性肝炎模型的實驗研究.中國病理生理雜誌,2011,27( 7):1389-1392.
48. 範文哲,李家平,楊建勇,等.無法手術切除的肝細胞癌TACE與RFA治療的Meta分析.中華普通外科學文獻:電子版,2010,5(1):62-67.
49. 王於, 連帆, 譚國勝, 範文哲, 向賢宏, 陳偉, 楊建勇, 李家平(通訊作者).同種異體脂肪幹細胞門脈移植對大鼠纖維化肝臟的影響.中國病理生理雜誌,2010,26 ( 11): 2197-2201.
50. 李家平,王於, 李鶴平, 楊建勇. 前列地爾對肝缺血再灌注損傷保護機制的實驗研究. 中華醫學雜誌.2009, 12(37):3653-3633.
51. 李家平,王海林,黃勇慧,李鶴平,王於,譚國勝, 陳偉,楊建勇.前列地爾對肝細胞癌動脈化療栓塞後肝血流灌注的影響。中華放射學雜誌,2009,43(10),1008-1013.
52. 李家平, 譚國勝, 黃勇慧, 陳偉, 楊建勇. 數字減影血管造影與介入治療在胃腸道動脈性出血中的套用價值.中華胃腸外科雜誌,2009,12 (3),252-256.
53. 李家平,黃勇慧,李鶴平,王於,楊建勇.肝缺血再灌注損傷血流動力學的CT灌注評價.中華放射學雜誌,2009,43(8),878-881.
54. 李家平, 陳偉, 黃勇慧, 江利, 楊建勇. 肝臟CT灌注成像測定肝有效血流量的準確性與可重複性研究. 中華放射學雜誌,2007,41(1),51-54.
55. 李家平, 楊建勇, 李桂生, 陳偉, 莊文權, 李智, 魯建生, 周欣. 腎母細胞瘤動脈化療栓塞的臨床病理學研究.中華放射學雜誌, 2002. 07.10; 36(4):644-648.
56. 李家平,楊建勇,陳偉,莊文權,王建波.西羅莫司對血管平滑肌細胞膠原合成影響的實驗研究.中華醫學雜誌.2007, 87(37):2653-2656.
57. 李家平,周奇,王海林,陳偉, 楊建勇.前列地爾Lipo-PGE1干預肝臟血流灌注的實驗研究.中國病理生理雜誌,2008,24(12):3421-3427.
58. 李家平,陳偉, 李智, 李桂生, 楊建勇. 腎母細胞瘤經動脈化療栓塞術療效機制探討. 中國病理生理雜誌,2007, 23(11):1195-1199.
59. 李家平, 陳偉, 黃勇慧, 江利, 楊建勇.CT灌注成像對經頸靜脈肝內門體分流術(TIPSS)後肝血流灌注變化的評價.中華外科學雜誌,2008,46(9):313-318 .
60. 李家平, 陳偉, 江利, 楊建勇.運用CT灌注成像監測介入斷流術後肝臟血流灌注的變化.中華外科學雜誌2007, 45(13):913-916.

相關詞條

熱門詞條

聯絡我們